Xenon Pharmaceuticals Target Price

Where could XENE trade next? Consensus target price: $76.

Get informed when a big investor buys or sells

+ Follow

Share Price

$63.18

Average Target Price

$75.50

19.5% upside

4 analysts in the last 4 months

High: $81 | Low: $69

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-10	H.C. WainwrightDouglas Tsao	$74	17.1% upside
2026-08-07	RBC CapitalBrian Abrahams	$81	28.2% upside
2026-05-10	Wells FargoBenjamin Burnett	$69	9.2% upside
2026-05-08	NeedhamSerge Belanger	$78	23.5% upside
2026-03-10	Deutsche Bank	$90	42.5% upside
2026-03-09	RBC Capital	$80	26.6% upside
2026-03-09	JefferiesAndrew Tsai	$100	58.3% upside
2026-03-09	GuggenheimYatin Suneja	$90	42.5% upside
2026-03-09	Morgan Stanley	$97	53.5% upside
2026-03-09	Robert W. Baird	$97	53.5% upside
2026-03-09	Stifel NicolausPaul Matteis	$89	40.9% upside
2026-03-09	JefferiesAndrew Tsai	$65	2.9% upside
2026-02-23	Wolfe Research	$60	5% downside
2026-02-10	Stifel Nicolaus	$66	4.5% upside
2025-11-04	RBC Capital	$58	8.2% downside
2025-11-04	Cantor FitzgeraldJosh Schimmer	$55	12.9% downside
2025-11-04	Wells FargoBenjamin Burnett	$44	30.4% downside
2025-02-28	Wedbush	$42	33.5% downside
2024-10-10	Raymond JamesDanielle Brill	$50	20.9% downside
2024-10-01	H.C. WainwrightDouglas Tsao	$53	16.1% downside
2024-08-09	WedbushLaura Chico	$49	22.4% downside
2024-06-18	RBC CapitalBrian Abrahams	$55	12.9% downside
2022-12-14	Goldman Sachs	$60	5% downside
2022-11-28	Wells Fargo	$50	20.9% downside
2022-11-11	Guggenheim	$49	22.4% downside
2022-10-18	Raymond JamesDanielle Brill	$52	17.7% downside
2022-08-11	Leerink Partners	$46	27.2% downside
2022-08-10	RBC Capital	$46	27.2% downside
2022-06-27	Wedbush	$41	35.1% downside
2022-05-11	RBC Capital	$41	35.1% downside

Xenon Pharmaceuticals (XENE) FAQ

Xenon Pharmaceuticals (XENE) currently reports a target price of $76. Use the charts on this page to explore Xenon Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Xenon Pharmaceuticals is $76, about 19.5% upside from the current share price of $63.18. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $76, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Xenon Pharmaceuticals, and consider following XENE for alerts when major investors trade the stock.

Xenon Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $76. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XENE with unrelated industries.